55 results on '"Kerbel, Robert S."'
Search Results
2. ErbB2/Her2-dependent downregulation of a cell death-promoting protein BLNK in breast cancer cells is required for 3D breast tumor growth
3. On coalescent angiogenesis and the remarkable flexibility of blood vessels
4. Immunostimulatory and anti-tumor metronomic cyclophosphamide regimens assessed in primary orthotopic and metastatic murine breast cancer
5. Metronomic chemotherapy offsets HIFα induction upon maximum‐tolerated dose in metastatic cancers
6. Microparticles from tumors exposed to radiation promote immune evasion in part by PD-L1
7. Variable impact of three different antiangiogenic drugs alone or in combination with chemotherapy on multiple bone marrow-derived cell populations involved in angiogenesis and immunity
8. Durability of cell line xenograft resection models to interrogate tumor micro-environment targeting agents
9. Vessel co-option in cancer
10. Therapeutic impact of Nintedanib with paclitaxel and/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer
11. Pre- and post-operative anti-PD-L1 plus anti-angiogenic therapies in mouse breast or renal cancer models of micro- or macro-metastatic disease
12. Preliminary Investigation of Focused Ultrasound-Facilitated Drug Delivery for the Treatment of Leptomeningeal Metastases
13. Preclinical impact of high dose intermittent antiangiogenic tyrosine kinase inhibitor pazopanib in intrinsically resistant tumor models
14. Consensus guidelines for the use and interpretation of angiogenesis assays
15. Non-angiogenic tumours and their influence on cancer biology
16. Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
17. Implications of vessel co-option in sorafenib-resistant hepatocellular carcinoma
18. Aflibercept and Ang1 supplementation improve neoadjuvant or adjuvant chemotherapy in a preclinical model of resectable breast cancer
19. Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect
20. Rationale for metronomic chemotherapy in phase III trials
21. Analysis of acquired resistance to metronomic oral topotecan chemotherapy plus pazopanib after prolonged preclinical potent responsiveness in advanced ovarian cancer
22. Anti-VEGF therapy reduces intestinal inflammation in Endoglin heterozygous mice subjected to experimental colitis
23. Endoglin and activin receptor-like kinase 1 heterozygous mice have a distinct pulmonary and hepatic angiogenic profile and response to anti-VEGF treatment
24. Drug rechallenge and treatment beyond progression—implications for drug resistance
25. Preclinical analysis of resistance and cross-resistance to low-dose metronomic chemotherapy
26. Strategies for Improving the Clinical Benefit of Antiangiogenic Drug Based Therapies for Breast Cancer
27. Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers
28. Correction: Antiangiogenic therapy: impact on invasion, disease progression, and metastasis
29. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis
30. Mouse models of advanced spontaneous metastasis for experimental therapeutics
31. Chemotherapy counteracted
32. Peering into the aftermath: The inhospitable host?
33. Raising the bar for cancer therapy models
34. On the development of models in mice of advanced visceral metastatic disease for anti-cancer drug testing
35. The authors reply
36. The multifaceted circulating endothelial cell in cancer: towards marker and target identification
37. Angiogenesis as a therapeutic target
38. The anti-angiogenic basis of metronomic chemotherapy
39. Radiation resistance of human melanoma analysed by retroviral insertional mutagenesis reveals a possible role for dopachrome tautomerase
40. Reply to “Limitations of combination anti-angiogenesis and chemotherapy”
41. Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner
42. Tyrosinase-related protein 2 as a mediator of melanoma specific resistance to cis-diamminedichloroplatinum(II): therapeutic implications
43. Interleukin-6 dependent induction of the cyclin dependent kinase inhibitor p21WAF1/CIP1 is lost during progression of human malignant melanoma
44. Establishing a Link between Oncogenes and Tumor Angiogenesis
45. A cancer therapy resistant to resistance
46. bFGF and tumor angiogenesis — Back in the limelight?
47. Impact of the cyclin–dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents
48. Growth advantage (“clonal dominance”) of metastatically competent tumor cell variants expressed under selective two- or three-dimensional tissue culture conditions
49. Potentiation of growth suppression and modulation of the antigenic phenotype in human melanoma cells by the combination of recombinant human fibroblast and immune interferons
50. Implications of immunological heterogeneity of tumours
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.